We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation (CONFIDENT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04558476
Recruitment Status : Active, not recruiting
First Posted : September 22, 2020
Last Update Posted : April 27, 2022
KCE Belgian Healthcare Knowledge Centre
Information provided by (Responsible Party):
Misset Benoit, University of Liege

Brief Summary:
The principal objective of the CONFIDENT trial is to assess the efficacy of two units (400-500 mL in total) of convalescent plasma, as compared to Standard of Care (SoC), to reduce day-28 mortality in patients with SARS-CoV-2 pneumonia who require mechanical ventilation.

Condition or disease Intervention/treatment Phase
Covid19 Mechanical Ventilation Complication Corona Virus Infection Respiratory Failure SARS (Severe Acute Respiratory Syndrome) Biological: Convalescent Plasma Other: Standard of Care Phase 2

Detailed Description:

Design : multicenter randomized openlabel, phase II trial.

Number of patients to include : 500 (250 with plasma, 250 without plasma).

The principal objective is to assess the efficacy of the treatment to reduce day-28 mortality in patients with SARS-CoV-2 pneumonia who require mechanical ventilation.

Hypothesis: Passive immunization with plasma collected from patients having contracted COVID-19 and developed specific antibodies may alleviate symptoms and viral load of SARS-CoV-2 and reduce mortality.

The patients will receive currently accepted standard of care for both COVID-19 and usual organ dysfunctions observed in such cases. half the patients will be administered either Convalescent plasma, depending on the randomization process. All patients will be followed-up for one year after inclusion. The study will be considered either positive or negative, based on the principal objective. This means that the product convalescent plasme will be considered effective if mortality at day 28 is lower is patients treated with convalescent plasma than without it. The follow-up will allow to assess a series of secondary objectives, addressing the evolution of organ failures, viral infection, inflammatory response and long-term physical of psychological impact of COVID-19. Interim analyses will be performed every 100 patients included in order to stop the trial if an exceptionally good or bad result is observed, to prevent using or not using the product appropriately in further patients. These analyses will be supervised by an independent committee.

The choice to include only those patients under mechanical ventilation for severe respiratory failure makes this study different from other trials testing convalescent plasma, as most trial include less severe patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 475 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter Randomized Trial to Assess the Efficacy of CONvalescent Plasma Therapy in Patients With Invasive COVID-19 and Acute Respiratory Failure Treated With Mechanical Ventilation: the CONFIDENT Trial
Actual Study Start Date : September 11, 2020
Actual Primary Completion Date : April 9, 2022
Estimated Study Completion Date : April 2023

Arm Intervention/treatment
Experimental: Convalescent Plasma
2 units of plasma ( 400-500ml) from 2 different donnors duration of treatment =2 h
Biological: Convalescent Plasma
2 units of convalescent plasma

Standard of care
Standard of care according the last gold standards
Other: Standard of Care
Gold Standards

Primary Outcome Measures :
  1. Vital status [ Time Frame: at day 28 ]
    dead or alive

Secondary Outcome Measures :
  1. day 90 mortality [ Time Frame: at day 90 ]
    dead or alive

  2. number of ventilator-free days at day 28 [ Time Frame: at day 28 ]
    to assess the ventilator free days

  3. number of renal replacement therapy free days at day 28 [ Time Frame: at day 28 ]
    to assess the number of renal replacement therapy free days

  4. number of vasopressors free-days at day 28 [ Time Frame: at day 28 ]
    to assess the number of vasopressors free-days

  5. use of ECMO before day 28 [ Time Frame: till day 28 ]
    to assess if ECMO was required

  6. value of the SOFA score at days 7, 14 and 28 [ Time Frame: Day 1, 7, 14, 28 ]
    to assess the value of SOFA score

  7. changes in SOFA scores (delta SOFA) over 7, 14 and 28 days [ Time Frame: Day 7, 14 and 28 days ]
    to assess the changes in SOFA scores (delta SOFA)

  8. assessment of the SARS-CoV-2 viral load [ Time Frame: Days 7, 14 and 28 ]
    assessment of the SARS-CoV-2 viral load, expressed as cycle threshold, [2] in the tracheal aspirates (for intubated patients) or nasopharyngeal swabs (for extubated patients) at days 7, 14 and 28

  9. blood C reactive protein (CRP) concentration [ Time Frame: Days 7, 14 and 28 ]
    to assess the concentrations of C reactive protein (CRP)

  10. ferritin concentration [ Time Frame: Days 7, 14 and 28 ]
    to assess the concentration of ferritin

  11. lymphocyte count [ Time Frame: Days 7, 14 and 28 ]
    to assess the count of lymphocyte

  12. length of stay in the acute care hospital [ Time Frame: through study completion, 1 year ]
    to assess the lenght of stay in the acute care

  13. location of the patient [ Time Frame: Day 90 ]
    to assess the location of the patient : acute care hospital, post acute care hospital, long-term residency, home

  14. Katz Index of independence in Activity Day Living functional score [ Time Frame: Day 90 and 365 ]
    to assess the Activity Day Living functional Min value: 0 = Low (patient very dependent) Max value: 6 = High (patient independent)

  15. Hospital Anxiety and Depression Scale (HADS) [ Time Frame: Day 90 and 365 ]
    to evaluate the anxiety-depression For each item 0-7 : Normal 8-10 : Bordeline abnormal (borderline case) 11-21 : Abnormal case

  16. Quality of life scale EQ-5D-5L [ Time Frame: Day 90 and 365 ]

    The EQ-5D-5L is composed of - the EQ-5D-5L descriptive system and the EQ Visual Analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Each level corresponds to 1-digit number expressing the level selected for that dimension.

    The EQ VAS corresponds to a 20 cm vertical, visual analogue scale raging from 'the best health you can imagine' to 'the worst health you can imagine'.

  17. Transfusion related adverse events [ Time Frame: till 28 days ]
    to assess the transfusion related adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age at least 18 years
  • hospitalization in an intensive care unit participating to the study
  • medical diagnosis with SARS-CoV-2 pneumonia as defined by both:

    • extended interstitial pneumonia on CT scan or a chest X-ray, consistent with viral pneumonia, within 10 days prior to inclusion
    • Positive result of SARS-CoV-2 PCR test, or any emerging and validated diagnostic laboratory test for COVID-19, within 15 days prior to inclusion
  • under mechanical ventilation administered through an endotracheal tube, for less than 5 days
  • prior Clinical Frailty Scale < 6.
  • written consent of the patient, or - if impossible - of a relative acting as the legal representative, or - if impossible - of a physician from a non-participating department of the same hospital acting as an impartial witness .

Exclusion Criteria:

  • Pregnancy
  • Prior episode of transfusion-related side effect
  • Medical decision to limit therapy
  • Current participation in another trial testing a COVID-19 therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04558476

Show Show 17 study locations
Sponsors and Collaborators
University of Liege
KCE Belgian Healthcare Knowledge Centre
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Misset Benoit, Professor, University of Liege
ClinicalTrials.gov Identifier: NCT04558476    
Other Study ID Numbers: 2020-003102-31
First Posted: September 22, 2020    Key Record Dates
Last Update Posted: April 27, 2022
Last Verified: April 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Misset Benoit, University of Liege:
Covid 19
Convalescent plasmatherapy
SARS Cov-2 pneumonia
Additional relevant MeSH terms:
Layout table for MeSH terms
Severe Acute Respiratory Syndrome
Coronavirus Infections
Respiratory Insufficiency
Respiratory Tract Infections
Pneumonia, Viral
Virus Diseases
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders